J&J said its bispecific antibody Rybrevant in a combination therapy outperformed AstraZeneca's (AZN)Tagrisso as a first-line option in lung cancer. Read more he...
Copy LinkSaveCommentsFollow us on Google for the latest stock newsFollow Seeking Alpha on Google for the latest stock news JHVEPhoto
The Janssen unit of Johnson & Johnson (NYSE:JNJ) announced Thursday that its bispecific antibody Rybrevant in a combination regimen outperformed AstraZeneca's (AZN) tyrosine kinase inhibitor osimertinib as a first-line therapy in certain patients with lung cancer.
Източник: seekingalpha.com
Тази статия е автоматично импортирана от външен източник. За оригиналното съдържание на пълната статия, моля посетете източника.